Reporting remotely on findings presented at the AACR 2020 Virtual Meeting, Fabrice Barlesi comments on studies from different countries sharing experience and knowledge acquired during the peak of first pandemic wave.
He firstly presents findings from the Paris area in France showing that special attention should be given to frail, patients with an haematological malignancy and to patients treated with chemotherapy in the past 3 months. He then goes on to discusse preliminary results from the TERAVOLT international registry and possible recruitment biases. Finally he looks into results from a study conducted in Wuhan, China, aiming to evaluate the impact of several types of cancer on COVID-19 disease outcomes.
- Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments (Fabrice Barlesi, Villejuif, France)
- TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion): First results of a global collaboration to address the impact of COVID-19 in patients with thoracic malignancies (Marina Garassino, Milan, Italy)
- The experience of treating patients with cancer during the COVID-19 pandemic in China (Hongbing Cai, Wuhan, China)